chr17:7577121:G>A Detail (hg19) (TP53)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr17:7,577,121-7,577,121 |
hg38 | chr17:7,673,803-7,673,803 View the variant detail on this assembly version. |
HGVS
Type | Transcript | Protein |
---|---|---|
RefSeq | NM_001126116.1:c.421C>T | NP_001119588.1:p.Arg141Cys |
NM_001276698.1:c.421C>T | NP_001263627.1:p.Arg141Cys | |
NM_000546.5:c.817C>T | NP_000537.3:p.Arg273Cys |
Summary
MGeND
Clinical significance |
![]() ![]() |
Variant entry | 215 |
GWAS entry | |
Disease area statistics | Show details |
Frequency
JP | HGVD:[No Data.] |
ToMMo:[No Data.] | |
NCBN:[No Data.] | |
NCBN(Hondo):[No Data.] | |
NCBN(Ryukyu):[No Data.] | |
East asia | ExAC:<0.001 |
Prediction
ClinVar
Clinical Significance |
![]() ![]() |
Review star | ![]() |
Show details |
Disease area statistics
MGeND
Clinical significance | Last evaluated | Condition | Origin | Submission ID | Submitter | Institute | Citation | Comment | Image |
---|---|---|---|---|---|---|---|---|---|
![]() |
2020/04/20 | bronchus or lung, unspecified |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | middle third of oesophagus |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | oesophagus, unspecified |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | fundus of stomach |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | body of stomach |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | pyloric antrum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | stomach, unspecified |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | duodenum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | jejunum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | descending colon |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | sigmoid colon |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | colon, unspecified |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | malignant neoplasm of rectosigmoid junction |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | malignant neoplasm of rectum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | extrahepatic bile duct |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | body of pancreas |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
Acute myeloblastic leukaemia |
![]() |
MGS000005
(TMGS000006) |
Keizo Horibe | National Hospital Organization Nagoya Medical Center | ||||
![]() |
Myelodysplastic syndromes |
![]() |
MGS000005
(TMGS000006) |
Keizo Horibe | National Hospital Organization Nagoya Medical Center | ||||
![]() |
2018/05/15 | stomach neoplasms |
![]() |
MGS000017
(TMGS000034) |
Kohei Miyazono | Tokyo University | |||
![]() |
2018/01/13 | breast, unspecified |
![]() |
MGS000028
(TMGS000049) |
Yukihide Momozawa | RIKEN |
30287823
|
||
![]() |
Colorectal |
![]() |
MGS000038
(TMGS000091) |
Manabu Muto Ichiro Kinoshita |
Kyoto University Department of Medical Oncology Faculty of Medicine and Graduate School of Medicine Hokkaido University |
||||
![]() |
NSCLC |
![]() |
MGS000038
(TMGS000091) |
Manabu Muto Ichiro Kinoshita |
Kyoto University Department of Medical Oncology Faculty of Medicine and Graduate School of Medicine Hokkaido University |
||||
![]() |
Endometrial |
![]() |
MGS000038
(TMGS000091) |
Manabu Muto Ichiro Kinoshita |
Kyoto University Department of Medical Oncology Faculty of Medicine and Graduate School of Medicine Hokkaido University |
||||
![]() |
Neoplasm of urachus (disorder) |
![]() |
MGS000021
(TMGS000080) |
Manabu Muto | Kyoto University | ||||
![]() |
Carcinoma of lower third of esophagus (disorder) |
![]() |
MGS000021
(TMGS000080) |
Manabu Muto | Kyoto University | ||||
![]() |
Carcinoma of breast (disorder) |
![]() |
MGS000021
(TMGS000080) |
Manabu Muto | Kyoto University | ||||
![]() |
Squamous cell carcinoma of esophagus (disorder) |
![]() |
MGS000021
(TMGS000080) |
Manabu Muto | Kyoto University | ||||
![]() |
Stomach |
![]() |
MGS000038
(TMGS000091) |
Manabu Muto Ichiro Kinoshita |
Kyoto University Department of Medical Oncology Faculty of Medicine and Graduate School of Medicine Hokkaido University |
||||
![]() |
Pancreas |
![]() |
MGS000038
(TMGS000091) |
Manabu Muto Ichiro Kinoshita |
Kyoto University Department of Medical Oncology Faculty of Medicine and Graduate School of Medicine Hokkaido University |
||||
![]() |
Malignant tumor of rectum (disorder) |
![]() |
MGS000023
(TMGS000082) |
Manabu Muto | Kyoto University | ||||
![]() |
Carcinoma of pancreas (disorder) |
![]() |
MGS000025
(TMGS000084) |
Manabu Muto | Kyoto University | ||||
![]() |
Primary malignant neoplasm of ovary (disorder)_Mucin (substance) |
![]() |
MGS000025
(TMGS000084) |
Manabu Muto | Kyoto University | ||||
![]() |
Ovarian cancer |
![]() |
MGS000018
(TMGS000110) |
Hitoshi Nakagama | National Cancer Center Japan |
30742731
|
|||
![]() |
Soft tissue sarcoma |
![]() |
MGS000018
(TMGS000110) |
Hitoshi Nakagama | National Cancer Center Japan |
30742731
|
|||
![]() |
Biliary cancer |
![]() |
MGS000018
(TMGS000110) |
Hitoshi Nakagama | National Cancer Center Japan |
30742731
|
|||
![]() |
Non-small cell lung cancer |
![]() |
MGS000018
(TMGS000110) |
Hitoshi Nakagama | National Cancer Center Japan |
30742731
|
|||
![]() |
2021/03/19 | breast |
![]() |
MGS000048
(TMGS000112) |
Yukihide Momozawa Koichi Matsuda |
RIKEN The University of Tokyo |
|||
![]() |
Pleuropulmonary blastoma (PPB) |
![]() |
MGS000001
(TMGS000154) |
Kenjiro Kosaki | Keio University | ||||
![]() |
2020/04/20 | other |
![]() |
MGS000039
(TMGS000092) |
Hitoshi Nakagama | National Cancer Center Japan |
29659903
|
||
![]() |
2020/04/20 | middle third of oesophagus |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | lower third of oesophagus |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | fundus of stomach |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | body of stomach |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | pyloric antrum |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | duodenum |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | caecum |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | ascending colon |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | transverse colon |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | descending colon |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | sigmoid colon |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | colon, unspecified |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | malignant neoplasm of rectosigmoid junction |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | malignant neoplasm of rectum |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | malignant neoplasm of gallbladder |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | head of pancreas |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | body of pancreas |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | ill-defined sites within the digestive system |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | bronchus or lung, unspecified |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | middle third of oesophagus |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | oesophagus, unspecified |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | fundus of stomach |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | body of stomach |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | pyloric antrum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | stomach, unspecified |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | duodenum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | jejunum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | caecum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | appendix |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | transverse colon |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | descending colon |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | colon, unspecified |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | malignant neoplasm of rectosigmoid junction |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | malignant neoplasm of rectum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | anal canal |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | |||
![]() |
2020/04/20 | ill-defined sites within the digestive system |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan |
ClinVar
Clinical significance | Last evaluated | Review status | Condition | Origin | Links |
---|---|---|---|---|---|
![]() ![]() |
2022-06-18 | criteria provided, multiple submitters, no conflicts | Hereditary cancer-predisposing syndrome |
![]() |
Detail |
![]() ![]() |
2024-02-20 | criteria provided, multiple submitters, no conflicts | Li-Fraumeni syndrome 1 |
![]() ![]() |
Detail |
![]() |
no assertion criteria provided | Malignant tumor of prostate |
![]() |
Detail | |
![]() |
2024-01-13 | criteria provided, multiple submitters, no conflicts | Li-Fraumeni syndrome |
![]() |
Detail |
![]() |
2023-03-22 | criteria provided, multiple submitters, no conflicts | not provided |
![]() ![]() |
Detail |
![]() |
2016-03-10 | no assertion provided | Breast neoplasm |
![]() |
Detail |
![]() |
2015-07-14 | no assertion criteria provided | Neoplasm |
![]() |
Detail |
![]() |
2015-07-14 | no assertion criteria provided | hepatocellular carcinoma |
![]() |
Detail |
![]() |
2014-10-02 | no assertion criteria provided | acute myeloid leukemia |
![]() |
Detail |
![]() |
2018-12-01 | no assertion criteria provided | Neoplasm of ovary |
![]() |
Detail |
![]() |
2023-09-05 | criteria provided, single submitter | Adrenocortical carcinoma, hereditary |
![]() |
Detail |
CIViC
Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
stomach carcinoma | Cisplatin,Etoposide,Mitomycin | C |
![]() |
![]() |
Sensitivity/Response | Somatic | 3 | 14514923 | Detail |
breast cancer | B |
![]() |
![]() |
Poor Outcome | Somatic | 3 | 16489069 | Detail | |
breast cancer | B |
![]() |
![]() |
Poor Outcome | Somatic | 3 | 9569050 | Detail | |
cancer | AMGMDS3 | D |
![]() |
![]() |
Resistance | Somatic | 4 | 25730903 | Detail |
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.441 | Li-Fraumeni syndrome 1 | NA | CLINVAR | Detail | |
0.122 | Neoplastic Syndromes, Hereditary | NA | CLINVAR | Detail | |
0.157 | pancreatic carcinoma | Using the whole-cell recording mode of the patch-clamp technique, functional ion... | BeFree | 14978241 | Detail |
0.002 | pancreatic carcinoma | Using the whole-cell recording mode of the patch-clamp technique, functional ion... | BeFree | 14978241 | Detail |
0.039 | Malignant neoplasm of pancreas | Using the whole-cell recording mode of the patch-clamp technique, functional ion... | BeFree | 14978241 | Detail |
0.002 | Malignant neoplasm of pancreas | Using the whole-cell recording mode of the patch-clamp technique, functional ion... | BeFree | 14978241 | Detail |
0.382 | osteosarcoma | Some of the genetic changes identified were in tumor suppressor genes previously... | BeFree | 22006429 | Detail |
0.134 | osteosarcoma | Some of the genetic changes identified were in tumor suppressor genes previously... | BeFree | 22006429 | Detail |
0.010 | Osteosarcoma of bone | Some of the genetic changes identified were in tumor suppressor genes previously... | BeFree | 22006429 | Detail |
0.031 | Osteosarcoma of bone | Some of the genetic changes identified were in tumor suppressor genes previously... | BeFree | 22006429 | Detail |
0.226 | melanoma | Two new mutations, the G542E exon 12 mutation variant of the FGFR2 gene and the ... | BeFree | 24858661 | Detail |
0.230 | Malignant neoplasm of prostate | NA | CLINVAR | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and recei... | CIViC Evidence | Detail |
Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild ty... | CIViC Evidence | Detail |
In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 ar... | CIViC Evidence | Detail |
Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 1... | CIViC Evidence | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Hereditary cancer-predisposing syndrome | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Li-Fraumeni syndrome 1 | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Malignant tumor of prostate | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Li-Fraumeni syndrome | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND not provided | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Breast neoplasm | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Neoplasm | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Hepatocellular carcinoma | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Acute myeloid leukemia | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Neoplasm of ovary | ClinVar | Detail |
NM_000546.6(TP53):c.817C>T (p.Arg273Cys) AND Adrenocortical carcinoma, hereditary | ClinVar | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Using the whole-cell recording mode of the patch-clamp technique, functional ion channels were elect... | DisGeNET | Detail |
Using the whole-cell recording mode of the patch-clamp technique, functional ion channels were elect... | DisGeNET | Detail |
Using the whole-cell recording mode of the patch-clamp technique, functional ion channels were elect... | DisGeNET | Detail |
Using the whole-cell recording mode of the patch-clamp technique, functional ion channels were elect... | DisGeNET | Detail |
Some of the genetic changes identified were in tumor suppressor genes previously identified as alter... | DisGeNET | Detail |
Some of the genetic changes identified were in tumor suppressor genes previously identified as alter... | DisGeNET | Detail |
Some of the genetic changes identified were in tumor suppressor genes previously identified as alter... | DisGeNET | Detail |
Some of the genetic changes identified were in tumor suppressor genes previously identified as alter... | DisGeNET | Detail |
Two new mutations, the G542E exon 12 mutation variant of the FGFR2 gene and the R273C mutation varia... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs121913343 dbSNP
- Genome
- hg19
- Position
- chr17:7,577,121-7,577,121
- Variant Type
- snv
- Reference Allele
- G
- Alternative Allele
- A
- East Asian Chromosome Counts (ExAC)
- 7940
- East Asian Allele Counts (ExAC)
- 0
- East Asian Heterozygous Counts (ExAC)
- 0
- East Asian Homozygous Counts (ExAC)
- 0
- East Asian Allele Frequency (ExAC)
- 0.0
- Chromosome Counts in All Race (ExAC)
- 112536
- Allele Counts in All Race (ExAC)
- 1
- Heterozygous Counts in All Race (ExAC)
- 1
- Homozygous Counts in All Race (ExAC)
- 0
- Allele Frequency in All Race (ExAC)
- 8.886045354375489E-6
- Variant (CIViC) (CIViC Variant)
- R273C
- Transcript 1 (CIViC Variant)
- ENST00000269305.4
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/121
- Summary (CIViC Variant)
- While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.
Genome browser